Teva Pharmaceutical has partnered with Modag for the development and licensing of the latter’s drug candidates, anle138b and sery433, for neurodegenerative disease?.
MODAG announced the clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson′s Disease (PD).